Research shows that patients who discontinue GLP-1 therapy experience an average weight regain of 50-70% of lost weight within one year
The most common site to inject is the bicep or a buttock cheek, although other possible injection sites include the hip area and upper thigh
Recent studies highlight how GLP-1 receptor agonistsincluding Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound)exhibit powerful anti-inflammatory effects
JAMA 318(15):14601470 Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrges JP, Lindegaard ML, Jensen CB, Atkin SL (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
This is the guide that changes everything